Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort

Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still needed. We treated a multi-ethnic cohort of 31 diffuse large B-cell lymphoma patients with axicabtagene ciloleucel...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabinovich, Emma, Pradhan, Kith, Sica, R. Alejandro, Bachier-Rodriguez, Lizamarie, Mantzaris, Ioannis, Kornblum, Noah, Shastri, Aditi, Gritsman, Kira, Goldfinger, Mendel, Verma, Amit, Braunschweig, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656085/
https://www.ncbi.nlm.nih.gov/pubmed/34886908
http://dx.doi.org/10.1186/s40164-021-00248-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656085/
https://www.ncbi.nlm.nih.gov/pubmed/34886908
http://dx.doi.org/10.1186/s40164-021-00248-9

Ejemplares similares